{
    "type": "ETF",
    "ucits": true,
    "leverage": false,
    "derivatives": false,
    "swaps": false,
    "inverse": false,
    "replication_method": "physical",
    "complex_factors": [],
    "classification": "non-complex",
    "supporting_data": "The Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF is a physically replicated ETF that tracks the MSCI ACWI IMI Genomic Innovation Select Index. The KIID and factsheet indicate that the fund uses direct replication (physical) to achieve its investment objective, which is a non-complex indicator under MiFID II. The fund does not employ leverage, inverse strategies, or synthetic replication. While the KIID mentions the use of derivatives for risk management and cost reduction, this is explicitly for efficient portfolio management (EPM) and not for creating additional risk or complexity. The underlying assets are liquid, publicly traded equities, and the fund does not exhibit any of the complexity triggers such as capital protection mechanisms, structured features, or significant counterparty risk. The risk profile is classified as level 6, which is high but not inherently indicative of complexity under MiFID II. The fund is UCITS-compliant, which further supports its classification as non-complex.",
    "confidence": 95
}